Companies

Investor Alert: Class Action Lawsuit Filed Against Intellia Therapeutics

Published February 12, 2025

ATLANTA, Feb. 12, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been initiated on behalf of shareholders of Intellia Therapeutics, Inc. ("Intellia" or the "Company") under the ticker NTLA. This legal action highlights allegations that the defendants made significant misrepresentations concerning the Company's Phase 1/2 clinical study evaluating NTLA-3001 aimed at treating alpha-1 antitrypsin deficiency (AATD) associated lung disease.

Investors who purchased shares of Intellia between July 30, 2024 and January 8, 2025 and have experienced substantial financial losses as a result are encouraged to understand their legal rights. Interested parties can reach out to Corey D. Holzer, Esq. at [email protected], or by calling toll-free at (888) 508-6832. Additional information is accessible on the firm’s website: www.holzerlaw.com/case/intellia-therapeutics/.

The deadline to apply for lead plaintiff status in this case is April 14, 2025.

Holzer & Holzer, LLC is known as an ISS top-rated securities litigation law firm for 2021, 2022, and 2023. The firm focuses on robust representation of shareholders and investors in litigation across the country, including shareholder class and derivative actions. Since its establishment in 2000, Holzer & Holzer attorneys have been pivotal in securing millions of dollars in recoveries for shareholders affected by corporate fraud and misconduct. Comprehensive details about the firm and its services can be found at www.holzerlaw.com. Corey Holzer is the attorney responsible for the content of this communication.

Market News and Data brought to you by Benzinga APIs

lawsuit, investors, Intellia